Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors’ reply

H. Bantel; F. Wandrer; B. Bock; M. M. Kirstein; K. Schulze-Osthoff

doi:10.1111/apt.13826

Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors’ reply

H. Bantel, F. Wandrer, B. Bock, M. M. Kirstein, K. Schulze-Osthoff

Medizinische Klinik I

Originalsprache	Englisch
Zeitschrift	Alimentary Pharmacology and Therapeutics
Jahrgang	45
Ausgabenummer	1
Seiten (von - bis)	184-185
Seitenumfang	2
ISSN	0269-2813
DOIs	https://doi.org/10.1111/apt.13826
Publikationsstatus	Veröffentlicht - 01.01.2017

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1111/apt.13826

Weitere Links

Link to publication in Scopus

Zitieren

@article{3d48d127298143de99afd6e6bc832c87,

title = "Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors{\textquoteright} reply",

author = "H. Bantel and F. Wandrer and B. Bock and Kirstein, \{M. M.\} and K. Schulze-Osthoff",

year = "2017",

month = jan,

day = "1",

doi = "10.1111/apt.13826",

language = "English",

volume = "45",

pages = "184--185",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc",

number = "1",

}

TY - JOUR

T1 - Letter: cytokeratin-18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors’ reply

AU - Bantel, H.

AU - Wandrer, F.

AU - Bock, B.

AU - Kirstein, M. M.

AU - Schulze-Osthoff, K.

PY - 2017/1/1

Y1 - 2017/1/1

UR - https://www.scopus.com/pages/publications/85002412607

U2 - 10.1111/apt.13826

DO - 10.1111/apt.13826

M3 - Letters

C2 - 27910155

AN - SCOPUS:85002412607

SN - 0269-2813

VL - 45

SP - 184

EP - 185

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 1

ER -